158 related articles for article (PubMed ID: 25402485)
1. The efficacy of the ribonucleotide reductase inhibitor Didox in preclinical models of AML.
Cook GJ; Caudell DL; Elford HL; Pardee TS
PLoS One; 2014; 9(11):e112619. PubMed ID: 25402485
[TBL] [Abstract][Full Text] [Related]
2. Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells.
Raje N; Kumar S; Hideshima T; Ishitsuka K; Yasui H; Chhetri S; Vallet S; Vonescu E; Shiraishi N; Kiziltepe T; Elford HL; Munshi NC; Anderson KC
Br J Haematol; 2006 Oct; 135(1):52-61. PubMed ID: 16925573
[TBL] [Abstract][Full Text] [Related]
3. Activation of caspases and induction of apoptosis by novel ribonucleotide reductase inhibitors amidox and didox.
Grusch M; Fritzer-Szekeres M; Fuhrmann G; Rosenberger G; Luxbacher C; Elford HL; Smid K; Peters GJ; Szekeres T; Krupitza G
Exp Hematol; 2001 May; 29(5):623-32. PubMed ID: 11376876
[TBL] [Abstract][Full Text] [Related]
4. Combination of inhibitors of lymphocyte activation (hydroxyurea, trimidox, and didox) and reverse transcriptase (didanosine) suppresses development of murine retrovirus-induced lymphoproliferative disease.
Mayhew CN; Sumpter R; Inayat M; Cibull M; Phillips JD; Elford HL; Gallicchio VS
Antiviral Res; 2005 Jan; 65(1):13-22. PubMed ID: 15652967
[TBL] [Abstract][Full Text] [Related]
5. Iron binding capacity of didox (3,4-dihydroxybenzohydroxamic acid) and amidox (3,4-dihydroxybenzamidoxime) new inhibitors of the enzyme ribonucleotide reductase.
Fritzer-Szekeres M; Novotny L; Vachalkova A; Findenig G; Elford HL; Szekeres T
Life Sci; 1997; 61(22):2231-7. PubMed ID: 9393942
[TBL] [Abstract][Full Text] [Related]
6. Suppression of retrovirus-induced immunodeficiency disease (murine AIDS) by trimidox and didox: novel ribonucleotide reductase inhibitors with less bone marrow toxicity than hydroxyurea.
Mayhew CN; Mampuru LJ; Chendil D; Ahmed MM; Phillips JD; Greenberg RN; Elford HL; Gallicchio VS
Antiviral Res; 2002 Nov; 56(2):167-81. PubMed ID: 12367722
[TBL] [Abstract][Full Text] [Related]
7. In vivo and in vitro comparison of the short-term hematopoietic toxicity between hydroxyurea and trimidox or didox, novel ribonucleotide reductase inhibitors with potential anti-HIV-1 activity.
Mayhew CN; Phillips JD; Greenberg RN; Birch NJ; Elford HL; Gallicchio VS
Stem Cells; 1999; 17(6):345-56. PubMed ID: 10606163
[TBL] [Abstract][Full Text] [Related]
8. Studies on the mechanisms of inhibition of L1210 cell growth by 3,4-dihydroxybenzohydroxamic acid and 3,4-dihydroxybenzamidoxime.
Tihan T; Elford HL; Cory JG
Adv Enzyme Regul; 1991; 31():71-83. PubMed ID: 1877400
[TBL] [Abstract][Full Text] [Related]
9. In vivo examination of hydroxyurea and the novel ribonucleotide reductase inhibitors trimidox and didox in combination with the reverse transcriptase inhibitor abacavir: suppression of retrovirus-induced immunodeficiency disease.
Sumpter LR; Inayat MS; Yost EE; Duvall W; Hagan E; Mayhew CN; Elford HL; Gallicchio VS
Antiviral Res; 2004 Jun; 62(3):111-20. PubMed ID: 15130534
[TBL] [Abstract][Full Text] [Related]
10. Ribonucleotide reductase inhibitors enhance cidofovir-induced apoptosis in EBV-positive nasopharyngeal carcinoma xenografts.
Wakisaka N; Yoshizaki T; Raab-Traub N; Pagano JS
Int J Cancer; 2005 Sep; 116(4):640-5. PubMed ID: 15818619
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of hemoglobin and F-cell production by targeting growth inhibition and differentiation of K562 cells with ribonucleotide reductase inhibitors (didox and trimidox) in combination with streptozotocin.
Iyamu WE; Adunyah SE; Fasold H; Horiuchi K; Elford HL; Asakura T; Turner EA
Am J Hematol; 2000 Apr; 63(4):176-83. PubMed ID: 10706760
[TBL] [Abstract][Full Text] [Related]
12. Iron binding capacity of didox (3,4 dihydroxybenzohydroxamic acid) and amidox (3,4 dihydroxybenzamidoxime) two inhibitors of the enzyme ribonucleotide reductase.
Fritzer-Szekeres M; Novotny L; Vachalkova A; Göbl R; Elford HL; Szekeres T
Adv Exp Med Biol; 1998; 431():599-604. PubMed ID: 9598136
[TBL] [Abstract][Full Text] [Related]
13. Synergistic cytotoxicity of the ribonucleotide reductase inhibitor didox (3,4-dihydroxy-benzohydroxamic acid) and the alkylating agent carmustine (BCNU) in 9L rat gliosarcoma cells and DAOY human medulloblastoma cells.
Horvath Z; Höchtl T; Bauer W; Fritzer-Szekeres M; Elford HL; Szekeres T; Tihan T
Cancer Chemother Pharmacol; 2004 Aug; 54(2):139-45. PubMed ID: 15133626
[TBL] [Abstract][Full Text] [Related]
14. DNA-protective activity of new ribonucleotide reductase inhibitors.
Rauko P; Romanova D; Miadokova E; Macakova K; Novotny L; Elford HL; Szekeres T
Anticancer Res; 1997; 17(5A):3437-40. PubMed ID: 9413183
[TBL] [Abstract][Full Text] [Related]
15. Effective use of ribonucleotide reductase inhibitors (Didox and Trimidox) alone or in combination with didanosine (ddI) to suppress disease progression and increase survival in murine acquired immunodeficiency syndrome (MAIDS).
Mayhew C; Oakley O; Piper J; Hughes NK; Phillips J; Birch NJ; Elford HL; Gallicchio VS
Cell Mol Biol (Noisy-le-grand); 1997 Nov; 43(7):1019-29. PubMed ID: 9449534
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis.
Nandy P; Lien EJ; Avramis VI
Anticancer Res; 1999; 19(3A):1625-33. PubMed ID: 10470093
[TBL] [Abstract][Full Text] [Related]
17. Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia.
Leitch C; Osdal T; Andresen V; Molland M; Kristiansen S; Nguyen XN; Bruserud Ø; Gjertsen BT; McCormack E
Oncotarget; 2016 Feb; 7(7):8105-18. PubMed ID: 26812881
[TBL] [Abstract][Full Text] [Related]
18. The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.
Hoang VT; Buss EC; Wang W; Hoffmann I; Raffel S; Zepeda-Moreno A; Baran N; Wuchter P; Eckstein V; Trumpp A; Jauch A; Ho AD; Lutz C
Int J Cancer; 2015 Aug; 137(3):525-36. PubMed ID: 25545165
[TBL] [Abstract][Full Text] [Related]
19. Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells.
Figul M; Söling A; Dong HJ; Chou TC; Rainov NG
Cancer Chemother Pharmacol; 2003 Jul; 52(1):41-6. PubMed ID: 12690517
[TBL] [Abstract][Full Text] [Related]
20. Didox (3,4-dihydroxybenzohydroxamic acid) suppresses IL-33-induced cytokine production in primary mouse mast cells.
Caslin HL; McLeod JJA; Spence AJ; Qayum AA; Kolawole EM; Taruselli MT; Paranjape A; Elford HL; Ryan JJ
Cell Immunol; 2017 Sep; 319():10-16. PubMed ID: 28750923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
